1Abraham SA, Waterhouse DN, Mayer LD,et al. The liposomal formulation of doxorubicin [ J ]. Methods Enzymol, 2005,391:71.
2Cleland JL. Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines [ J ]. Biotechnol Prog, 1998,14 : 102.
5Yoshimoto Y, Kawada M, Ikeda D, et al. Involvement of doxorubicin- induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo [ J ]. Int J Immunopharmacol,2005,5 : 281.
4[1]Shimose S, Sugita T, Nitta Y, Kubo T, Ikuta Y, Murakami T. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma [J]. Int J Oncol,2001;19(3): 585-589.
5[2]Nakao K, Otsuki Y, Akao Y, Ito Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis [J]. Med Electron Microsc,2000;33(1): 44-50.
6[3]Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure [J]. J Pharmacol Exp Ther, 2002;300(3): 862-867.
7[4]Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: Evidence for selective impairment of myofibrillar creatine kinase [J]. Br J Pharmacol, 2002;135(3): 581-588.
8[5]Safra T, Muggia F, Jeffers S, Tsao-wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg·m-2 [J]. Ann Oncol, 2000;11(8): 1029-1033.
9[6]Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J]. J Clin Oncol, 2001;19(5): 1444-1454.
